ITCI Intra Cellular Therapies Inc

Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.

$46.49  +1.24 (2.74%)
As of 09/30/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/27/2013
Outstanding shares:  94,401,745
Average volume:  758,923
Market cap:   $4,271,678,961
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BHCB0P4
Valuation   (See tab for details)
PE ratio:   -14.47
PB ratio:   5.52
PS ratio:   41.48
Return on equity:   -38.29%
Net income %:   -294.72%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy